3 502127262226Reads by AI crawlersClaude0ChatGPT2Google · Gemini1Perplexity2Meta AI7Microsoft · Copilot2Amazon6Apple2China (ByteDance, Huawei, Baidu…)2ByteDance (Doubao)2Others26Total50Counted by the name each crawler declares; requests found to be impersonating one are left out. Google · Gemini includes Googlebot, the search crawler whose index Google also uses for its AI features. Other search engines and bots are under Others.
Four studies across different populations all point to one gene, ADIPOQ, as the strongest genetic driver of adiponectin, a hormone inversely linked to type 2 diabetes risk.
What this condition connects to
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
Prevalence
Not applicable in the usual sense — adiponectin is a continuously measured hormone level, not a diagnosis. The largest study behind this page examined 45,891 people across multiple ancestries (Dastani et al. 2012, PMID:22479202).
Inheritance
Polygenic but with one dominant locus: ADIPOQ, the gene directly encoding adiponectin, was the strongest signal in essentially every study behind this page, across multiple independent populations.
Adiponectin is a hormone produced by fat cells that is inversely associated with type 2 diabetes and cardiovascular disease risk — higher adiponectin generally tracks with better metabolic health, the opposite pattern from most fat-derived hormones. It is highly heritable, and genetic studies across several populations keep landing on the same gene.
Four studies, one gene that keeps winning
Richards et al. 2009 meta-analysed 8,531 people, validated in 6,202 more, and found the strongest signal — as in nearly every study of adiponectin — at ADIPOQ itself, the gene that directly encodes the hormone. The same study identified a novel gene, ARL15, also linked to higher coronary heart disease risk. This page's rs1648707, in ADIPOQ, is that paper's own strongest finding.
A separate 2010 study of 4,659 European individuals confirmed ADIPOQ as the major adiponectin gene outright — this page's rs17366568, also in ADIPOQ, is that study's own finding.
Dastani et al. 2012 ran the largest study, meta-analysing 39,883 Europeans and cross-checking against 4,232 African Americans and 1,776 Asians (45,891 people total). The study found 8 novel loci and confirmed 2 previously known ones — again including ADIPOQ — plus 2 more from the cross-ethnic analysis. A risk score built from adiponectin-lowering alleles was linked to higher type 2 diabetes risk, triglycerides, waist-to-hip ratio, and fasting glucose and insulin — but, in a genuinely counterintuitive twist, also to lower BMI and lower HDL cholesterol. This page's TRIB1, ADIPOQ, DNAH10, GNL3, and PEPD variants all come from this study.
A 2014 East Asian meta-analysis found a genuinely novel locus near WDR11-FGFR2 — but this page's variant from that study, rs10937273, is in ADIPOQ once again, part of that study's confirmed rather than novel findings.
Positions joined since this page was written
What this is The text above discusses the variants this page was written around. Since then the catalogue has joined 11 more positions to it, by shared trait or shared paper. They are listed here by the paper each came from; the text does not describe them, and each variant page carries that study's own record.
Adiponectin is measured directly with a blood test, not estimated from genotype, and no variant on this page is used clinically to interpret an adiponectin result or assess diabetes risk. The variants here describe genetic contributors to baseline adiponectin level, not a predictive test.
Adiponectin's counterintuitive relationships with other metabolic traits — the Dastani et al. 2012 finding that adiponectin-lowering alleles link to both worse (higher triglycerides, higher diabetes risk) and seemingly better (lower BMI) outcomes — is an active research question, not something this page or any clinical test resolves.
Related variants MyGeneLog™ checks for
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Adiponectin Levels comes down to these specific, well-studied positions — not a diagnosis.
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 8 of 20 linked studies with a resolved discovery ancestry.
10.0%
25.0%
European · 10.0% East Asian · 5.0% Other named ancestries (African American or Afro-Caribbean, Asian unspecified) · 25.0% Not yet resolved · 60.0%
3 502127262226Reads by AI crawlersClaude0ChatGPT2Google · Gemini1Perplexity2Meta AI7Microsoft · Copilot2Amazon6Apple2China (ByteDance, Huawei, Baidu…)2ByteDance (Doubao)2Others26Total50Counted by the name each crawler declares; requests found to be impersonating one are left out. Google · Gemini includes Googlebot, the search crawler whose index Google also uses for its AI features. Other search engines and bots are under Others.
Quoting this page
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Adiponectin is a hormone produced by fat cells that is inversely associated with type 2 diabetes and cardiovascular disease risk — higher levels generally track with better metabolic health.
What do these four studies agree on?
All four point to ADIPOQ, the gene that directly encodes adiponectin, as the strongest or a confirmed genetic driver of adiponectin level, across European, African American, and East Asian populations.
Does higher genetic adiponectin mean lower diabetes risk?
The largest study found a genuinely mixed picture: adiponectin-lowering alleles linked to higher diabetes risk and triglycerides, but also to lower BMI — a pattern not fully explained.
Does this page predict my adiponectin level or diabetes risk?
No individual variant does. These are population-level statistical associations, and adiponectin is measured directly with a blood test, not estimated from genotype.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.